Welcome to our dedicated page for BioAtla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on BioAtla stock.
BioAtla, Inc. (NASDAQ: BCAB) is a clinical-stage biopharmaceutical company committed to advancing the treatment of cancer through its innovative protein therapeutic products. Headquartered in San Diego, California, with a strategic presence in Beijing, China, BioAtla leverages its proprietary Conditionally Active Biologics (CAB) technology to develop novel monoclonal and bispecific antibodies.
The core of BioAtla's work lies in the engineering of antibodies that become active under the unique conditions of the tumor microenvironment, thus improving tumor selectivity and reducing on-target toxicity. This technology aims to enhance the therapeutic index of drug candidates, ultimately providing safer and more effective cancer treatments.
BioAtla's pipeline includes several promising candidates. Mecbotamab vedotin (BA3011) and ozuriftamab vedotin (BA3021) are in Phase 2 clinical testing, targeting AXL and ROR2 respectively. Another key asset, evalstotug (BA3071), is a CTLA-4 inhibitor designed to minimize systemic toxicity and facilitate safer combination therapies with anti-PD-1 antibodies. Furthermore, the company's first bispecific T-cell engager antibody, BA3182, is undergoing Phase 1 trials, focusing on EpCAM and engaging CD3 expressing T cells.
BioAtla has an extensive patent portfolio, with over 750 patents filed, more than 475 of which have been granted. This robust intellectual property coverage supports the company's competitive edge in the biotechnology sector.
Recent updates include the initiation of a Phase 1 clinical trial for BA3361, a next-generation CAB-Nectin4-ADC, which demonstrated superior activity in pancreatic cancer models. The company also continues to build strategic partnerships and collaborations to advance its research and commercialize its products effectively.
For further information and the latest updates, visit BioAtla's official website or contact their investor relations team.
BioAtla, a clinical-stage biotechnology company, announced the sale of 9,745,128 shares at $6.67 each, aiming for approximately $65 million in gross proceeds. The underwritten offering is expected to close around November 8, 2022, pending customary conditions. Proceeds will support research, Phase 2 trials for two antibody-drug conjugates, and general corporate purposes. Notable investors include Acuta Capital Partners and Janus Henderson Investors. J.P. Morgan is the book-running manager for this offering, which is registered under an effective Form S-3 with the SEC.
BioAtla, Inc. (Nasdaq: BCAB) announced promising interim results from its Phase 2 studies for mecbotamab vedotin (BA3011) in non-small cell lung cancer (NSCLC), showing significant antitumor activity. The company reported a cash balance of $178.1 million as of September 30, 2022, sufficient to fund operations into 2H24. R&D expenses increased to $19.8 million, while net loss widened to $25.8 million. Ongoing clinical programs include CAB-CTLA-4 (BA3071), with the third dosing cohort underway. A conference call will be held today at 4:30 PM ET for further details.
BioAtla (Nasdaq: BCAB) will host a conference call on November 3, 2022, at 4:30 p.m. ET to discuss its financial results for Q3 2022 and provide business highlights. The press release with these results will be available prior to the call, and a replay will be accessible afterward. BioAtla focuses on Conditionally Active Biologic antibody therapeutics aimed at treating solid tumors. The company boasts an extensive patent portfolio with over 600 patents, and it is advancing two first-in-class CAB programs currently in Phase 2 clinical trials.
Himalaya Therapeutics has reported promising interim results for its clinical trial of HTBA3011 in Non-Small Cell Lung Cancer (NSCLC) and certain sarcomas. The trial shows an objective response rate of 43% in non-squamous NSCLC patients and 50% partial responses in undifferentiated pleomorphic sarcoma patients. As a result, the company plans to advance NSCLC to the registrational stage and proceed with Phase 2 enrollment for sarcomas. This success underlines the potential of Himalaya's Conditionally Active Biologics technology in addressing significant unmet medical needs.
BioAtla, Inc. (Nasdaq: BCAB) reported promising preliminary observations from its Phase 2 study of mecbotamab vedotin (BA3011) in non-small cell lung carcinoma (NSCLC). The candidate demonstrated a 33% objective response rate (ORR) in evaluable NSCLC patients. The company anticipates full interim data by 4Q22 and plans to initiate additional studies in undifferentiated pleomorphic sarcoma and osteosarcoma. With a cash balance of $202.3 million, BioAtla expects funding to last into 2H24, supporting continued clinical development across multiple programs.
BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biotechnology company, announced its participation in the 2022 BTIG Biotechnology Conference. The fireside chat is scheduled for August 8, 2022, at 12:00 p.m. ET in New York, NY. BioAtla specializes in Conditionally Active Biologic (CAB) therapeutics for treating solid tumors, featuring products in Phase 2 clinical testing, including mecbotamab vedotin and ozuriftamab vedotin. The company holds more than 600 patents, enhancing its innovative CAB technology and product candidates.
BioAtla (BCAB) announced a conference call on August 9, 2022, at 4:30 p.m. ET to discuss its Q2 2022 financial results and recent business highlights. The call will be accessible via webcast and telephone. BioAtla focuses on Conditionally Active Biologic (CAB) therapies for solid tumors, with two CAB programs in Phase 2 clinical trials and one in Phase 1/2. The company boasts over 500 patents covering its technology, emphasizing its innovative approach to antibody therapeutics aimed at increasing efficacy while reducing toxicity.
BioAtla, a clinical-stage biotechnology firm, announced a corporate update and one-on-one investor meetings at the Jefferies Global Healthcare Conference in New York, scheduled for June 8-10, 2022. CEO Jay M. Short and President Scott Smith will present on June 8 at 10:00 a.m. ET. The event will feature formal remarks and a webcast available on the company's website. BioAtla is known for its Conditionally Active Biologic (CAB) technology, with two CAB programs currently in Phase 2 testing.
BioAtla, Inc. (BCAB) reported significant progress in its clinical trials, with top-line interim data from the Phase 2 study of Mecbotamab vedotin (BA3011) in sarcoma showing promising results. Partial responses were noted in 33% of undifferentiated pleomorphic sarcoma patients, while the progression-free survival (PFS) rate reached 67% in osteosarcoma patients. The company ended Q1 2022 with a cash balance of $219.4 million, expected to fund operations into mid-2024. First quarter net loss was $24.3 million, an increase from $18.7 million in Q1 2021.
BioAtla, Inc. (Nasdaq: BCAB) announced a conference call on May 4, 2022, at 4:30 p.m. ET to discuss Q1 2022 financial results and provide topline data from the Phase 2 study of mecbotamab vedotin (BA3011) in sarcoma. The call will include updates on ongoing clinical programs like BA3011, ozuriftamab vedotin (BA3021), and CAB-CTLA-4 (BA3071). The press release with financial results will be available before the call on the company’s website.
FAQ
What is the current stock price of BioAtla (BCAB)?
What is the market cap of BioAtla (BCAB)?
What is BioAtla, Inc. known for?
Where are BioAtla's main operations located?
What are BioAtla's leading drug candidates?
What is CAB technology?
How extensive is BioAtla's patent portfolio?
What recent developments has BioAtla announced?
Who can I contact for more information about BioAtla?
What types of cancers are BioAtla's treatments targeting?
What are the benefits of BioAtla's CAB technology?
Where can I find BioAtla's latest news and updates?
